| Literature DB >> 28900602 |
Marion Straßer1,2, Joachim H X Schrauth3,4, Sofia Dembski1,5,6, Daniel Haddad3,7, Bernd Ahrens8,9, Stefan Schweizer8,9, Bastian Christ5, Alevtina Cubukova5, Marco Metzger5,6, Heike Walles5,6, Peter M Jakob3,4, Gerhard Sextl1,2.
Abstract
New multifunctional nanoparticles (NPs) that can be used as contrast agents (CA) in different imaging techniques, such as photoluminescence (PL) microscopy and magnetic resonance imaging (MRI), open new possibilities for medical imaging, e.g., in the fields of diagnostics or tissue characterization in regenerative medicine. The focus of this study is on the synthesis and characterization of CaF2:(Tb3+,Gd3+) NPs. Fabricated in a wet-chemical procedure, the spherical NPs with a diameter of 5-10 nm show a crystalline structure. Simultaneous doping of the NPs with different lanthanide ions, leading to paramagnetism and fluorescence, makes them suitable for MR and PL imaging. Owing to the Gd3+ ions on the surface, the NPs reduce the MR T1 relaxation time constant as a function of their concentration. Thus, the NPs can be used as a MRI CA with a mean relaxivity of about r = 0.471 mL·mg-1·s-1. Repeated MRI examinations of four different batches prove the reproducibility of the NP synthesis and determine the long-term stability of the CAs. No cytotoxicity of NP concentrations between 0.5 and 1 mg·mL-1 was observed after exposure to human dermal fibroblasts over 24 h. Overall this study shows, that the CaF2:(Tb3+,Gd3+) NPs are suitable for medical imaging.Entities:
Keywords: calcium fluoride nanoparticles; magnetic resonance imaging (MRI); multifunctional nanoparticles; multimodal imaging; photoluminescence
Year: 2017 PMID: 28900602 PMCID: PMC5530611 DOI: 10.3762/bjnano.8.148
Source DB: PubMed Journal: Beilstein J Nanotechnol ISSN: 2190-4286 Impact factor: 3.649
Figure 1DLS measurement of the CaF2:(Tb3+,Gd3+) NPs (number- and volume-weighted). Inset: TEM micrograph of the same particles. The size of the NPs is in the range of 5–10 nm and they have a spherical shape.
Figure 2In the upper part, the XRD pattern of the CaF2:(Tb3+,Gd3+) NPs (d = 5–10 nm, doping concentration of Tb3+ and Gd3+: 1 mol %) is plotted. Below a reference spectrum from the database JCPDS (Joint Committee on Powder Diffraction Standards, Powder Diffraction File: 035-0816) is shown. The reflexes of both spectra appear at the same diffraction angles 2θ, which indicates the crystalline structure (CaF2 = fluorite) of the NPs. The blue points mark the peaks of NH4Cl.
Representative outcome of an ICP-OES measurement of CaF2:(Tb3+,Gd3+) NPs.
| element | amount of substance (mol) | doping (mol %) |
| F | 0.46 | |
| Ca | 0.20 | |
| Tb | 0.02 | 0.87 |
| Gd | 0.02 | 0.92 |
Figure 3Normalized photoluminescence spectrum of CaF2:(Tb3+,Gd3+) NPs at an excitation wavelength of λexc = 254 nm. The emission spectrum shows several maxima (490, 542, 586 and 622 nm), which represent the Tb3+-related transitions from the 5D4 excited state to the energy levels indicated. The maximum intensity occurs in the green spectral range at a wavelength of λ = 542 nm. Inset: CaF2:(Tb3+,Gd3+) NP powder under UV light excitation (λexc = 254 nm). The green luminescence matches the maximum of the emission spectrum.
Figure 4a) T1-weighted MR image of the CaF2:(Tb3+,Gd3+) NPs with different concentrations in the range from 0.4 to 18.2 mg·mL−1 (1–10). I–III are reference samples of water and two concentrations of Magnevist. The different concentrations result in observable differences of the signal intensities. In b) the following T1-map with a corresponding color range from 0 to 2000 ms is shown. c) The relaxivity (r = 0.385 ± 0.030 mL·mg−1·s−1) arises from the slope by plotting the relaxation rates over the concentrations. The errors of the relaxivity are given by the minimal and maximal slope.
Relaxivities of four different batches: as prepared (row 1) and nine months after fabrication (row 2).
| batches | 1 | 2 | 3 | 4 | |
| relaxivity | as prepared | 0.438 ± 0.044 | 0.443 ± 0.044 | 0.522 ± 0.052 | 0.451 ± 0.045 |
| nine months after fabrication | 0.385 ± 0.038 | 0.388 ± 0.039 | 0.467 ± 0.046 | 0.400 ± 0.040 | |
Figure 5Relaxivity values of the four batches as prepared (green) and nine months (grey) after fabrication. Considering the error bars, the measured relaxivities directly after the preparation overlap with each other. After nine months a decrease of the relaxivity of each batch can be observed.
Figure 6Sedimentation study of the CaF2:(Tb3+,Gd3+) NPs (5 mg·mL−1) in Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% FCS stabilized with Melpers®2450 and non-stabilized: a) photographs of the stabilized NPs and the non-stabilized NPs 24 h after dispersing the NPs in FCS-containing cell-culture medium and b) absorbance measurement (λabs = 700 nm) of the samples over a period of 24 h.
Figure 7a) Representative microscopic image of hdF 24 h after treatment with the NPs (c = 1 mg·mL−1). b) Cell viability 24 h after adding CaF2:(Tb3+,Gd3+) NPs at concentrations between 0.5 and 1 mg·mL−1 to hdF. 10% SDS was used for the positive control. All samples have cell viabilities over 80% and therefore the NPs can be classified as non-cytotoxic (n = 3).